Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Epinephrine (KP001) in Healthy Volunteers
NCT06963411Phase 1Completed
- Sponsor
- Kokua Pharma
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KP001 in anaphylaxis (3 arms), sponsored by Kokua Pharma. Primary endpoints: Maximal observed plasma concentration, Area under the concentration-time curve from time zero to last measurable concentration and 4 more. Started May 2025; status: completed.
02
Drugs
KP001
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT06963411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963411.